Selected research
Industry Research
Acquired Immunodeficiency Syndrome Industry Research Report 2026
Market perspective
The global Acquired Immunodeficiency Syndrome market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Acquired Immunodeficiency Syndrome market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Acquired Immunodeficiency Syndrome market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Acquired Immunodeficiency Syndrome market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Acquired Immunodeficiency Syndrome include Takeda, Sanofi, Novartis, Pfizer, Amgen, Merck KGaA, Daiichi Sankyo Company, Biogen and AstraZeneca Eli Lilly and Company and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Acquired Immunodeficiency Syndrome market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Acquired Immunodeficiency Syndrome.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Acquired Immunodeficiency Syndrome Market by Company
Takeda
Sanofi
Novartis
Pfizer
Amgen
Merck KGaA
Daiichi Sankyo Company
Biogen
AstraZeneca Eli Lilly and Company
Actelion
Acquired Immunodeficiency Syndrome Segment by Type
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Acquired Immunodeficiency Syndrome Segment by Application
Hospital Pharmacy
Retail Pharmacy
Others
Acquired Immunodeficiency Syndrome Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acquired Immunodeficiency Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acquired Immunodeficiency Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acquired Immunodeficiency Syndrome.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Acquired Immunodeficiency Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Applications
- Hospital Pharmacy
- Retail Pharmacy
- Others
Companies covered
- Takeda
- Sanofi
- Novartis
- Pfizer
- Amgen
- Merck KGaA
- Daiichi Sankyo Company
- Biogen
- AstraZeneca Eli Lilly and Company
- Actelion
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Acquired Immunodeficiency Syndrome by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 2.2.3 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 2.3 Acquired Immunodeficiency Syndrome by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacy
- 2.3.3 Retail Pharmacy
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Acquired Immunodeficiency Syndrome Breakdown Data by Type
- 3.1 Global Acquired Immunodeficiency Syndrome Historic Market Size by Type (2021-2026)
- 3.2 Global Acquired Immunodeficiency Syndrome Forecasted Market Size by Type (2027-2032)
4 Acquired Immunodeficiency Syndrome Breakdown Data by Application
- 4.1 Global Acquired Immunodeficiency Syndrome Historic Market Size by Application (2021-2026)
- 4.2 Global Acquired Immunodeficiency Syndrome Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Acquired Immunodeficiency Syndrome Market Perspective (2021-2032)
- 5.2 Global Acquired Immunodeficiency Syndrome Growth Trends by Region
- 5.2.1 Global Acquired Immunodeficiency Syndrome Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Acquired Immunodeficiency Syndrome Historic Market Size by Region (2021-2026)
- 5.2.3 Acquired Immunodeficiency Syndrome Forecasted Market Size by Region (2027-2032)
- 5.3 Acquired Immunodeficiency Syndrome Market Dynamics
- 5.3.1 Acquired Immunodeficiency Syndrome Industry Trends
- 5.3.2 Acquired Immunodeficiency Syndrome Market Drivers
- 5.3.3 Acquired Immunodeficiency Syndrome Market Challenges
- 5.3.4 Acquired Immunodeficiency Syndrome Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Acquired Immunodeficiency Syndrome Players by Revenue
- 6.1.1 Global Top Acquired Immunodeficiency Syndrome Players by Revenue (2021-2026)
- 6.1.2 Global Acquired Immunodeficiency Syndrome Revenue Market Share by Players (2021-2026)
- 6.2 Global Acquired Immunodeficiency Syndrome Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Acquired Immunodeficiency Syndrome Head Office and Area Served
- 6.4 Global Acquired Immunodeficiency Syndrome Players, Product Type & Application
- 6.5 Global Acquired Immunodeficiency Syndrome Manufacturers Established Date
- 6.6 Global Acquired Immunodeficiency Syndrome Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Acquired Immunodeficiency Syndrome Market Size (2021-2032)
- 7.2 North America Acquired Immunodeficiency Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Acquired Immunodeficiency Syndrome Market Size by Country (2021-2026)
- 7.4 North America Acquired Immunodeficiency Syndrome Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Acquired Immunodeficiency Syndrome Market Size (2021-2032)
- 8.2 Europe Acquired Immunodeficiency Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Acquired Immunodeficiency Syndrome Market Size by Country (2021-2026)
- 8.4 Europe Acquired Immunodeficiency Syndrome Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size (2021-2032)
- 9.2 Asia-Pacific Acquired Immunodeficiency Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Acquired Immunodeficiency Syndrome Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Acquired Immunodeficiency Syndrome Market Size (2021-2032)
- 10.2 South America Acquired Immunodeficiency Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Acquired Immunodeficiency Syndrome Market Size by Country (2021-2026)
- 10.4 South America Acquired Immunodeficiency Syndrome Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size (2021-2032)
- 11.2 Middle East & Africa Acquired Immunodeficiency Syndrome Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Acquired Immunodeficiency Syndrome Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Acquired Immunodeficiency Syndrome Business (2021-2026)
- 12.1.4 Takeda Acquired Immunodeficiency Syndrome Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Sanofi
- 12.2.1 Sanofi Company Information
- 12.2.2 Sanofi Business Overview
- 12.2.3 Sanofi Revenue in Acquired Immunodeficiency Syndrome Business (2021-2026)
- 12.2.4 Sanofi Acquired Immunodeficiency Syndrome Product Portfolio
- 12.2.5 Sanofi Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Acquired Immunodeficiency Syndrome Business (2021-2026)
- 12.3.4 Novartis Acquired Immunodeficiency Syndrome Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Pfizer
- 12.4.1 Pfizer Company Information
- 12.4.2 Pfizer Business Overview
- 12.4.3 Pfizer Revenue in Acquired Immunodeficiency Syndrome Business (2021-2026)
- 12.4.4 Pfizer Acquired Immunodeficiency Syndrome Product Portfolio
- 12.4.5 Pfizer Recent Developments
- 12.5 Amgen
- 12.5.1 Amgen Company Information
- 12.5.2 Amgen Business Overview
- 12.5.3 Amgen Revenue in Acquired Immunodeficiency Syndrome Business (2021-2026)
- 12.5.4 Amgen Acquired Immunodeficiency Syndrome Product Portfolio
- 12.5.5 Amgen Recent Developments
- 12.6 Merck KGaA
- 12.6.1 Merck KGaA Company Information
- 12.6.2 Merck KGaA Business Overview
- 12.6.3 Merck KGaA Revenue in Acquired Immunodeficiency Syndrome Business (2021-2026)
- 12.6.4 Merck KGaA Acquired Immunodeficiency Syndrome Product Portfolio
- 12.6.5 Merck KGaA Recent Developments
- 12.7 Daiichi Sankyo Company
- 12.7.1 Daiichi Sankyo Company Company Information
- 12.7.2 Daiichi Sankyo Company Business Overview
- 12.7.3 Daiichi Sankyo Company Revenue in Acquired Immunodeficiency Syndrome Business (2021-2026)
- 12.7.4 Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Product Portfolio
- 12.7.5 Daiichi Sankyo Company Recent Developments
- 12.8 Biogen
- 12.8.1 Biogen Company Information
- 12.8.2 Biogen Business Overview
- 12.8.3 Biogen Revenue in Acquired Immunodeficiency Syndrome Business (2021-2026)
- 12.8.4 Biogen Acquired Immunodeficiency Syndrome Product Portfolio
- 12.8.5 Biogen Recent Developments
- 12.9 AstraZeneca Eli Lilly and Company
- 12.9.1 AstraZeneca Eli Lilly and Company Company Information
- 12.9.2 AstraZeneca Eli Lilly and Company Business Overview
- 12.9.3 AstraZeneca Eli Lilly and Company Revenue in Acquired Immunodeficiency Syndrome Business (2021-2026)
- 12.9.4 AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Product Portfolio
- 12.9.5 AstraZeneca Eli Lilly and Company Recent Developments
- 12.10 Actelion
- 12.10.1 Actelion Company Information
- 12.10.2 Actelion Business Overview
- 12.10.3 Actelion Revenue in Acquired Immunodeficiency Syndrome Business (2021-2026)
- 12.10.4 Actelion Acquired Immunodeficiency Syndrome Product Portfolio
- 12.10.5 Actelion Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst